{"name":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","slug":"shanghai-fosun-pharmaceutical-industrial-development-co-ltd","ticker":"","exchange":"","domain":"shanghaifosunindustrialdevelopment.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"FCN-159","genericName":"FCN-159","slug":"fcn-159","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"FCN-159","genericName":"FCN-159","slug":"fcn-159","phase":"phase_2","mechanism":"FCN-159 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQUGFtRXltSEtSRkdPZ2ZPVWN5WHNSdl90SDJLd3FzR0lnMEk3cTJmLU5TZ2FlOHBNUU1NZ2J0ZC1wWVJNRnN3UkVuV2tXX0pJRFk3aWc4UnhWbzY3d1pKeHcwZTVBQWd5c1FmQzRTZ1FaOXhBTlI0VGNtdUJFUy1PakNzb3VMZDFxZlpGY0JzTGF2b0FidmFZa3FhVUdydmtFNHFTNEI3SG8yY3Z2?oc=5","date":"2026-04-02","type":"regulatory","source":"BioWorld News","summary":"Fosun gains clinical trial approval in China for FXB-0871 - BioWorld News","headline":"Fosun gains clinical trial approval in China for FXB-0871","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxNVXFqNTJPNnRQYnNwOWNkYk5tb1NqNnl0NkVXcGxyclA3VjZfZjFkYS1kMkV6MUs4b3NQb2M3dzFpVW83RUxHblhRa2ZsME1GVzYzbl92Njcxcml4WUdFLU40eXh4UUo1ZU9lR3BFcnNkQTVRRzJueldMY0hjc3B4ZkVLVVRwWEhMcGV2cHlfYTUxbTRWMmFhWEZQRkhsVGx3ZG9kZV9kMWl4SlBDdUlhSGRxSThySFotQnBwQ3hNZjNTTUV3N093cU5FNnpJQkNkSEpJN2xpbnJPaVFWNU1LOF91MGRnanBXbTE5bks3Zw?oc=5","date":"2026-04-01","type":"trial","source":"The Globe and Mail","summary":"Fosun Pharma Wins China Trial Nod for Teva-Partnered Cancer Drug FXB0871 - The Globe and Mail","headline":"Fosun Pharma Wins China Trial Nod for Teva-Partnered Cancer Drug FXB0871","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNbFVNOVpVeTdGbERGbGtVTTJDSmVNNER6T1RWUlhvMkE3bTY3RDgzaFZkamFPOFR5eUZjUXQ3SXZ4dUhhVjZhV01teEJzbzhvNW9XU3NMeS16Z1h1dE10aVdadE5VNk9Ua1NRU003ZkVTV3FzYTlta3JRS0ZSVmFjQ1Zzc191N3Z2RUlMSkY5OE1NNTBDRXpvQTM3cGhkRnRSYnd4Z2U1b2U4UQ?oc=5","date":"2026-03-31","type":"regulatory","source":"Moomoo","summary":"Fosun Pharma (02196): FXB0871 has been approved for clinical trials for locally advanced or metastatic solid tumors. - Moomoo","headline":"Fosun Pharma (02196): FXB0871 has been approved for clinical trials for locally advanced or metastatic solid tumors.","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOeXJtaklNZDlrcXdZNi1ZWnp2NXZEX1FTZGhBeTd3Mjc4SDFPSjI5QVNndUdNbXlkaFNMalNaWjZRRGtWclRrWHNtODR1NDhfX1p3bnlWOEFGbXdZVDJwUHB2a0tSRklaYXJqTDBSdTVSeVBQa2lTcld0MUJQZWhIbzlQYWdTdVhHMEhHRXBUeW1vaGFWUkJ1MENLVnRHUQ?oc=5","date":"2026-03-31","type":"regulatory","source":"富途牛牛","summary":"Fosun Pharma (600196.SH): The drug FXB0871 developed by its holding subsidiary has been approved for clinical trials. - 富途牛牛","headline":"Fosun Pharma (600196.SH): The drug FXB0871 developed by its holding subsidiary has been approved for clinical trials. - ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPVGZ1NldoRW9qZEhIWEN2cXB2VzRUQlRuNDUwN29WQ1dvOXJubkVSUmNxZEdlUHpLUE5hVERZUVNwV3JHeThlbnhCdUJiZ0NqOUxKcXBlbWtlbDQtaVVGRVpuNl9iQnA1RTFtUFlZUzBYRmROcnlnY3ZiR2tfQjhqQzduNUEzNGhidjRLZ1FSbDdOdjVTdmhPdWdTQQ?oc=5","date":"2026-03-18","type":"trial","source":"openPR.com","summary":"HER2 Positive Breast Cancer Clinical Trial Pipeline Appears - openPR.com","headline":"HER2 Positive Breast Cancer Clinical Trial Pipeline Appears","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNSms0SzlULWh2VU5kRkNBaHluQ0FwcktUVHFqZl9Lb2ZsR0lEczdOOU52X0Fqc3lBQW5YcFZIZXNHQjhXYTQ4aFQza3k0cEs0R3c4RkN5X1FRTWRMbDBpbmp0dFdkZEJYcGlPaENqWm91VVVZb2JjbWhPV3NFcFctMnIxRHBBTlVqRFpHbDhnMXJzUkFhS2JZbXp6ZjE3V2dHWnBKdzdFb0tHczV6?oc=5","date":"2025-12-11","type":"deal","source":"FinanceAsia","summary":"Fosun Pharma subsidiary signs potential $1.9bn Pfizer licence deal - FinanceAsia","headline":"Fosun Pharma subsidiary signs potential $1.9bn Pfizer licence deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQanJmQktDZE1kWU5PRjdXc1gtbVhKMW9yYmltUmdteG43dU1MRC1KdFN0WDAtQUlwaTMzeGctTnZQVndFWEI0ZVZ1eU9Wc0JwMV9VTnVPd05zRFlKbGE3U2xqR0Qwc2hodFhlWEhVeEFMUkt2UTZYQVdNOElNY0pjWGxXazA5T1kzTGhMLTNuMk9CY2NYMEZHTHBDOFY2Skt2RkhGaE9QNFJEVHFRS1lvUUR3?oc=5","date":"2025-12-10","type":"deal","source":"BioSpectrum Asia","summary":"Yao Pharma licenses oral GLP-1R agonists to Pfizer for $1.93 B - BioSpectrum Asia","headline":"Yao Pharma licenses oral GLP-1R agonists to Pfizer for $1.93 B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQb2JkSkItZnBjMDgxTzhwdlQ0OVV3VzNZZzlpX1VIMnRVR1I1M3p5ZDZSNlR3NkxrS0NvVU5hblEwUERRYnVZU0dGVGR6X24wT3B1NlMyYk90c3hseFhKdE5KdFlRbGpQalBaVy1OX0pLczQwcUd5V2RXcGtKcW9uSEtTSm0zcklZ?oc=5","date":"2025-12-09","type":"deal","source":"Yahoo Finance","summary":"Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement - Yahoo Finance","headline":"Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOSVBZUFFlQXF1cHpmU1pRMlNZV1JyajluVVF0QUlLY0oxYzhUMXNWR0FyWTB2d1J2WlBBVHVLNWlkWUVEQlFRXzJRUjJNYnlBZWpXNXVhOXQyUTBMM0h2S3JkVWlVT19TektmZmlHSnJzdHgyWHY5dEhoLWtRXzlZVGlIb0NuamlfYTQ5ZW94ZGUyQQ?oc=5","date":"2025-06-18","type":"deal","source":"PharmaTimes","summary":"Teva and Fosun Pharma partner on early-stage oncology drug - PharmaTimes","headline":"Teva and Fosun Pharma partner on early-stage oncology drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxOTHJOVWF0RDhlNEgwNVZFd2RhUU15MWQxbmpGZWh2VUU0NFVqSnpYZUc3R1BqWWVtTUxCeENLa3h6X25ZYTNOYkZZZ0FxcG9VdFdvd2gxYVdIcEVqN1BRZTRaWkQwX1E0azBNVlRBd19NUVRVazY3THBWZ1RwZGlIMnZUeEZzVjlXLU5YaXhNcDYyb3lTcWstV0JoWk5ydWdoR1A0aVJOTWdsUGRPRnpIWWRvWEFyOGRoRTY4Z0lJdkplTjRBVURsbWE1WFpUUUhQME8tZHNsMFl6TDgzeVI3WGtfWmhhRGl3eHc?oc=5","date":"2025-06-16","type":"deal","source":"Koreabizwire","summary":"Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology - Koreabizwire","headline":"Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Onc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigJBVV95cUxQVG83MkVlbHJxUHF3d1hPVzFoRlBEVHhhS2Q1ZGJfSlNLcE5wMVUtMEhBN1RaOVh4S1FXbWZmblBHdTU0N3B0RWYxbmswX0ZTczB2OUd4TnZXOEN5N29hWjJEVE41VzBXVjlEUDZjTXpCWjdCV2dEWTFBVXJ4NWFOcGZrS1liZjZtNHBpU2FWc0IwVVVSVFY1MjNySGo4Z0JaZDBVUHZrdEQ0Qk1qQ3VOZFJmdEdRTWJ1OGRYLW1Help6VzM3OFdPeHMtTWtuQnFEd3BocHp3azktaTJUYnhPZXktUmRpdGNOZnBUd3BDWVd2OXpFS0t6UFNnZ0ZhNUZzdFJiUFNHS2tRUQ?oc=5","date":"2025-02-17","type":"pipeline","source":"prnewswire.com","summary":"Fosun Pharma Deeply Embraces AI, Self-developed PharmAID Decision Intelligence Platform Boosts Efficient Innovation - prnewswire.com","headline":"Fosun Pharma Deeply Embraces AI, Self-developed PharmAID Decision Intelligence Platform Boosts Efficient Innovation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQM1hFZHBFc1docXFKWDgyS1VNVzBKdjdRMV83X1lvdFJUaWtzSmZ2WmNueXR3clc2dmhFRGU5Y0xDbjVwWjBieElUZVBXRUN1R0lQNFRoQnNlSW1hendSbWIzdHZHYmFBOXlDdkVRamZpM0RqWnZiWVpKM2Jyb3JYVThLQzN4TUJNcU0wZ3FaY1RZUUljQWdwWWZqd1A?oc=5","date":"2022-09-07","type":"pipeline","source":"newswire.com","summary":"Neovii and Fosun Pharma Enter Into an Exclusive Agreement - newswire.com","headline":"Neovii and Fosun Pharma Enter Into an Exclusive Agreement","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}